Compared to I/R + Ang II group, CAV-1-shRNA decreased myocardial infarct size (Fig. 4A-B), reduced the plasma CK-MB level and cTn-I level (Fig. 4C-D), increased LVEF and LVFS, and decreased LVESd and LVEDd (Fig. 4E-I); while ACE2-shRNA increased myocardial infarct size (Fig. 4A-B), raised the plasma CK-MB level and cTn-I level (Fig. 4C-D), decreased LVEF and LVFS, and enlarged LVESd and LVEDd (Fig. 4E-I). The gene discussed is CAV1; the disease is myocardial infarction.